Fredag 2 Januari | 10:04:30 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Annexin has laid the foundation for continued clinical development
2025-12-19 10:25:00

2025 has been characterised by activities that strengthen the clinical program fordrug candidate ANXV. During the year, Annexin Pharmaceuticals has advanced its phase IIa-activities in ophthalmology, established an international medical expert council and represented the company at a number of international congresses where dialogues with potential licensing partners have been held. The company is now poised for business and the next stage of clinical development.

Read the article at biostock.se:
Annexin has laid the foundation for continued clinical development
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden